Drug Profile
BNC 101
Alternative Names: BNC-101; ET-101Latest Information Update: 02 Aug 2022
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Bionomics; Carina Biotech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action LGR5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Colorectal cancer; Solid tumours
Most Recent Events
- 02 Aug 2022 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Australia (IV)
- 02 Aug 2022 Discontinued - Phase-I for Colorectal cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Australia (IV)
- 02 Aug 2022 Discontinued - Preclinical for Cancer in Australia (Parenteral)